PACS Group Inc. reports third quarter revenue of $5.25 billion to $5.35 billion

Reuters
Nov 20, 2025
<a href="https://laohu8.com/S/PACS">PACS Group</a> Inc. reports third quarter revenue of $5.25 billion to $5.35 billion

PACS Group Inc. reported third quarter 2025 results, with full-year revenue expected to be between $5.3 billion and $5.4 billion and adjusted EBITDA projected in the range of $480 million to $490 million. The company completed a restatement of previous financial statements and is now current with SEC filing obligations. PACS Group's portfolio now includes 320 healthcare operations across 17 states, with ownership of 51 facilities and purchase options on an additional 59 facilities. The company continues to pursue growth through a combination of leasing, acquisitions, and evaluating opportunities to acquire both high-performing and underperforming operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PACS Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002001184-25-000072), on November 19, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10